GeneTether Therapeutics (XCNQ:GTTX) Additional Paid-In Capital : C$2.19 Mil(As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics Additional Paid-In Capital?

GeneTether Therapeutics's quarterly additional paid-in capital declined from Jun. 2023 (C$1.92 Mil) to Sep. 2023 (C$1.88 Mil) but then increased from Sep. 2023 (C$1.88 Mil) to Dec. 2023 (C$2.19 Mil).

GeneTether Therapeutics's annual additional paid-in capital increased from Dec. 2021 (C$1.01 Mil) to Dec. 2022 (C$2.01 Mil) and increased from Dec. 2022 (C$2.01 Mil) to Dec. 2023 (C$2.19 Mil).

GeneTether Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for GeneTether Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics Additional Paid-In Capital Chart

GeneTether Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

1.01

2.01

2.19

GeneTether Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial								2.01	1.95	1.92	1.88	2.19

GeneTether Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

GeneTether Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneTether Therapeutics (XCNQ:GTTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3

Website

https://www.genetether.com

GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines